Cargando…

Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma

IMPORTANCE: Immune checkpoint blockade (ICB) has improved the survival of patients with advanced melanoma. Durable responses are observed for 40% to 60% of patients, depending on treatment regimens. However, there is still large variability in the response to treatment with ICB, and patients experie...

Descripción completa

Detalles Bibliográficos
Autores principales: Bolte, Laura A., Lee, Karla A., Björk, Johannes R., Leeming, Emily R., Campmans-Kuijpers, Marjo J. E., de Haan, Jacco J., Vila, Arnau Vich, Maltez-Thomas, Andrew, Segata, Nicola, Board, Ruth, Harries, Mark, Lorigan, Paul, de Vries, Elisabeth G. E., Nathan, Paul, Fehrmann, Rudolf, Bataille, Véronique, Spector, Tim D., Hospers, Geke A. P., Weersma, Rinse K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936383/
https://www.ncbi.nlm.nih.gov/pubmed/36795408
http://dx.doi.org/10.1001/jamaoncol.2022.7753
_version_ 1784890218469392384
author Bolte, Laura A.
Lee, Karla A.
Björk, Johannes R.
Leeming, Emily R.
Campmans-Kuijpers, Marjo J. E.
de Haan, Jacco J.
Vila, Arnau Vich
Maltez-Thomas, Andrew
Segata, Nicola
Board, Ruth
Harries, Mark
Lorigan, Paul
de Vries, Elisabeth G. E.
Nathan, Paul
Fehrmann, Rudolf
Bataille, Véronique
Spector, Tim D.
Hospers, Geke A. P.
Weersma, Rinse K.
author_facet Bolte, Laura A.
Lee, Karla A.
Björk, Johannes R.
Leeming, Emily R.
Campmans-Kuijpers, Marjo J. E.
de Haan, Jacco J.
Vila, Arnau Vich
Maltez-Thomas, Andrew
Segata, Nicola
Board, Ruth
Harries, Mark
Lorigan, Paul
de Vries, Elisabeth G. E.
Nathan, Paul
Fehrmann, Rudolf
Bataille, Véronique
Spector, Tim D.
Hospers, Geke A. P.
Weersma, Rinse K.
author_sort Bolte, Laura A.
collection PubMed
description IMPORTANCE: Immune checkpoint blockade (ICB) has improved the survival of patients with advanced melanoma. Durable responses are observed for 40% to 60% of patients, depending on treatment regimens. However, there is still large variability in the response to treatment with ICB, and patients experience a range of immune-related adverse events of differing severity. Nutrition, through its association with the immune system and gut microbiome, is a poorly explored but appealing target with potential to improve the efficacy and tolerability of ICB. OBJECTIVE: To investigate the association between habitual diet and response to treatment with ICB. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study (the PRIMM study) was conducted in cancer centers in the Netherlands and UK and included 91 ICB-naive patients with advanced melanoma who were receiving ICB between 2018 and 2021. EXPOSURES: Patients were treated with anti–programmed cell death 1 and anti–cytotoxic T lymphocyte–associated antigen 4 monotherapy or combination therapy. Dietary intake was assessed through food frequency questionnaires before treatment. MAIN OUTCOMES AND MEASURES: Clinical end points were defined as overall response rate (ORR), progression-free survival at 12 months (PFS-12), and immune-related adverse events that were grade 2 or higher. RESULTS: There were a total of 44 Dutch participants (mean [SD] age, 59.43 [12.74] years; 22 women [50%]) and 47 British participants (mean [SD] age, 66.21 [16.63] years; 15 women [32%]). Dietary and clinical data were prospectively collected from 91 patients receiving ICB between 2018 and 2021 for advanced melanoma in the UK and the Netherlands. Logistic generalized additive models revealed positive linear associations between a Mediterranean dietary pattern that was high in whole grains, fish, nuts, fruit, and vegetables and the probability of ORR and PFS-12 (probability of 0.77 for ORR; P = .02; false discovery rate, 0.032; effective degrees of freedom, 0.83; probability of 0.74 for PFS-12; P = .01; false discovery rate, 0.021; effective degrees of freedom, 1.54). CONCLUSIONS AND RELEVANCE: This cohort study found a positive association between a Mediterranean diet, a widely recommended model of healthy eating, and response to treatment with ICB. Large prospective studies from different geographies are needed to confirm the findings and further elucidate the role of diet in the context of ICB.
format Online
Article
Text
id pubmed-9936383
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-99363832023-02-18 Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma Bolte, Laura A. Lee, Karla A. Björk, Johannes R. Leeming, Emily R. Campmans-Kuijpers, Marjo J. E. de Haan, Jacco J. Vila, Arnau Vich Maltez-Thomas, Andrew Segata, Nicola Board, Ruth Harries, Mark Lorigan, Paul de Vries, Elisabeth G. E. Nathan, Paul Fehrmann, Rudolf Bataille, Véronique Spector, Tim D. Hospers, Geke A. P. Weersma, Rinse K. JAMA Oncol Brief Report IMPORTANCE: Immune checkpoint blockade (ICB) has improved the survival of patients with advanced melanoma. Durable responses are observed for 40% to 60% of patients, depending on treatment regimens. However, there is still large variability in the response to treatment with ICB, and patients experience a range of immune-related adverse events of differing severity. Nutrition, through its association with the immune system and gut microbiome, is a poorly explored but appealing target with potential to improve the efficacy and tolerability of ICB. OBJECTIVE: To investigate the association between habitual diet and response to treatment with ICB. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study (the PRIMM study) was conducted in cancer centers in the Netherlands and UK and included 91 ICB-naive patients with advanced melanoma who were receiving ICB between 2018 and 2021. EXPOSURES: Patients were treated with anti–programmed cell death 1 and anti–cytotoxic T lymphocyte–associated antigen 4 monotherapy or combination therapy. Dietary intake was assessed through food frequency questionnaires before treatment. MAIN OUTCOMES AND MEASURES: Clinical end points were defined as overall response rate (ORR), progression-free survival at 12 months (PFS-12), and immune-related adverse events that were grade 2 or higher. RESULTS: There were a total of 44 Dutch participants (mean [SD] age, 59.43 [12.74] years; 22 women [50%]) and 47 British participants (mean [SD] age, 66.21 [16.63] years; 15 women [32%]). Dietary and clinical data were prospectively collected from 91 patients receiving ICB between 2018 and 2021 for advanced melanoma in the UK and the Netherlands. Logistic generalized additive models revealed positive linear associations between a Mediterranean dietary pattern that was high in whole grains, fish, nuts, fruit, and vegetables and the probability of ORR and PFS-12 (probability of 0.77 for ORR; P = .02; false discovery rate, 0.032; effective degrees of freedom, 0.83; probability of 0.74 for PFS-12; P = .01; false discovery rate, 0.021; effective degrees of freedom, 1.54). CONCLUSIONS AND RELEVANCE: This cohort study found a positive association between a Mediterranean diet, a widely recommended model of healthy eating, and response to treatment with ICB. Large prospective studies from different geographies are needed to confirm the findings and further elucidate the role of diet in the context of ICB. American Medical Association 2023-02-16 2023-05 /pmc/articles/PMC9936383/ /pubmed/36795408 http://dx.doi.org/10.1001/jamaoncol.2022.7753 Text en Copyright 2023 Bolte LA et al. JAMA Oncology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Brief Report
Bolte, Laura A.
Lee, Karla A.
Björk, Johannes R.
Leeming, Emily R.
Campmans-Kuijpers, Marjo J. E.
de Haan, Jacco J.
Vila, Arnau Vich
Maltez-Thomas, Andrew
Segata, Nicola
Board, Ruth
Harries, Mark
Lorigan, Paul
de Vries, Elisabeth G. E.
Nathan, Paul
Fehrmann, Rudolf
Bataille, Véronique
Spector, Tim D.
Hospers, Geke A. P.
Weersma, Rinse K.
Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma
title Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma
title_full Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma
title_fullStr Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma
title_full_unstemmed Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma
title_short Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma
title_sort association of a mediterranean diet with outcomes for patients treated with immune checkpoint blockade for advanced melanoma
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936383/
https://www.ncbi.nlm.nih.gov/pubmed/36795408
http://dx.doi.org/10.1001/jamaoncol.2022.7753
work_keys_str_mv AT boltelauraa associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma
AT leekarlaa associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma
AT bjorkjohannesr associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma
AT leemingemilyr associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma
AT campmanskuijpersmarjoje associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma
AT dehaanjaccoj associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma
AT vilaarnauvich associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma
AT maltezthomasandrew associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma
AT segatanicola associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma
AT boardruth associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma
AT harriesmark associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma
AT loriganpaul associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma
AT devrieselisabethge associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma
AT nathanpaul associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma
AT fehrmannrudolf associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma
AT batailleveronique associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma
AT spectortimd associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma
AT hospersgekeap associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma
AT weersmarinsek associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma